Research shows promising treatments against skin cancer
Two new experimental treatments against advanced melanoma have shown promise in keeping the deadly skin cancer at bay, according to research presented in the United States on Monday.
The trial on Trametinib included 322 people, of whom 214 took the experimental drug while the rest did standard chemotherapy, researchers said at the American Society of Clinical Oncology meeting in Chicago.
More than 22 percent of those on Trametinib responded to treatment compared to eight percent in the chemo group.
The Trametinib group also experienced a median 4.8 month period in which the cancer did not advance, and saw their risk of dying from skin cancer diminish by 46 percent compared to the chemo group -- 81 percent were still alive after six months of treatment compared to 67 percent in the control group.
The phase III trial was the first to evaluate a treatment against melanoma that inhibits a protein known as MEK, and may help about half of all melanoma patients who have a mutation in the BRAF gene that fuels tumor growth.
"This is the first in a new class of targeted drugs that could benefit patients with melanoma who have BRAF mutations," said Caroline Robert, head of Dermatology at the Institute Gustave Roussy in Paris, France.
"The findings show that targeting the MEK molecular pathway is a viable strategy for treating many people with the disease," Robert added.
"Trametinib is likely to become another first-line treatment option for patients with advanced melanoma."
One other therapy on the market, vemurafenib (Zelboraf), is currently approved in the United States and Europe for advanced melanoma.
The second trial involved Dabrafenib, which also targets cancers with the BRAF mutation, and showed a 70 percent lower risk of cancer progression compared to those treated with chemotherapy alone (5.1 months versus 2.7 months.
The phase III trial included 250 participants who had not been treated with any drug prior to enrollment and who had been diagnosed with inoperable melanoma, 187 of whom took the experimental drug while the rest were given standard chemotherapy.
Half of patients in the Dabrafenib group responded to therapy, compared to six percent of patients treated with a chemotherapy treatment known as dacarbazine.
The median time in which the cancer did not progress was 5.1 months in the Dabrafenib group compared to 2.7 months in the control group.
More study is needed to determine the overall survival rate, researchers said.
"These findings represent another advance for melanoma and form the foundation for further studies to evaluate the role of Dabrafenib in combination with other drugs," said lead investigator Axel Hauschild, a professor of dermatology at University of Kiel in Germany.
According to the US National Cancer Institute, there are about 76,000 new cases of melanoma diagnosed each year in the United States and more than 9,100 deaths.
(c) 2012 AFP
- ASCO: Dabrafenib/Trametinib active in metastatic melanoma May 17, 2012 | not rated yet | 0
- New drug, Vemurafenib, doubles survival of metastatic melanoma patients Mar 01, 2012 | not rated yet | 0
- Dabrafenib shrinks melanoma brain metastases in phase I clinical trial May 17, 2012 | not rated yet | 0
- New melanoma drug Zelboraf nearly doubles survival in majority of patients Feb 22, 2012 | not rated yet | 0
- New drug shrinks brain tumours in melanoma patients May 21, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...
Cancer 3 hours ago | not rated yet | 0
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...
Cancer 3 hours ago | not rated yet | 0
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer 6 hours ago | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer 7 hours ago | 5 / 5 (1) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer 7 hours ago | 5 / 5 (3) | 0
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
1 hour ago | 5 / 5 (1) | 0 |
Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.
1 hour ago | not rated yet | 0
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
7 hours ago | 5 / 5 (3) | 0 |
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
4 hours ago | 5 / 5 (1) | 0 |
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
4 hours ago | 5 / 5 (2) | 0 |
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
22 hours ago | 4.9 / 5 (9) | 0 |